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Abstract: Background:  Whether blood eosinophil counts and exhaled nitric 
oxide (FeNO) are associated with important outcomes in mild asthma is 
unclear.  
Methods:  This question was explored in a pre-specified analysis of a 52-
week, open-label, randomized, parallel-group trial in patients with mild 
asthma receiving only reliever inhalers, comparing salbutamol 200µg as-
needed, maintenance budesonide 200µg twice-daily with salbutamol as 
needed, and budesonide/formoterol 200/6µg as-needed. Outcomes were 
compared between patients with blood eosinophils of <0.15, 0.15-<0.3 and 
≥0.3x109/L; FeNO  of <20, 20-50 and >50ppb; and a composite score based 
on both.   
Results: The proportion of patients randomised to as-needed salbutamol 
having a severe exacerbation increased progressively with increasing 
blood eosinophil sub-group (4.1%, 6.5% and 19.5%; p=0.014).  There were 
no significant interactions between either biomarker and the effect of 
as-needed budesonide/formoterol compared with as-needed salbutamol for 
either exacerbations or severe exacerbations. However, there were 
significant interactions between blood eosinophil sub-groups and the 
effect of maintenance budesonide compared with as needed salbutamol for 
exacerbations (p<0.001) and severe exacerbations (p<0.001). Maintenance 
budesonide was more effective than as-needed salbutamol in patients with 
eosinophils ≥0.3x109/L for exacerbations (odds ratio 0.13; 95% CI 0.05-
0.33) and severe exacerbations (0.11; 0.03-0.45). This was not the case 
for eosinophils <0.15x109/L (odds ratio for exacerbations 1.15; 0.51-1.28 
and severe exacerbations 5.72; 0.97-33.6). There was no consistent 
interaction between treatment response and FeNO or the composite score. 
Conclusions: In patients with mild asthma the effects of as-needed 
budesonide/formoterol on exacerbations are independent of biomarker 
profile, whereas the benefits of maintenance inhaled budesonide are 
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ABSTRACT   
Background:  Whether blood eosinophil counts and exhaled nitric oxide (FeNO) are associated 
with important outcomes in mild asthma is unclear.  
Methods:  This question was explored in a pre-specified analysis of a 52-week, open-label, 
randomized, parallel-group trial in patients with mild asthma receiving only reliever inhalers, comparing 
salbutamol 200µg as-needed, maintenance budesonide 200µg twice-daily with salbutamol as needed, 
and budesonide/formoterol 200/6µg as-needed. Outcomes were compared between patients with blood 
eosinophils of <0.15, 0.15-<0.3 and ≥0.3x109/L; FeNO  of <20, 20-50 and >50ppb; and a composite 
score based on both.   
Results: The proportion of patients randomised to as-needed salbutamol having a severe 
exacerbation increased progressively with increasing blood eosinophil sub-group (4.1%, 6.5% and 
19.5%; p=0.014).  There were no significant interactions between either biomarker and the effect of 
as-needed budesonide/formoterol compared with as-needed salbutamol for either exacerbations or 
severe exacerbations. However, there were significant interactions between blood eosinophil sub-
groups and the effect of maintenance budesonide compared with as needed salbutamol for 
exacerbations (p<0.001) and severe exacerbations (p<0.001). Maintenance budesonide was more 
effective than as-needed salbutamol in patients with eosinophils ≥0.3x109/L for exacerbations 
(odds ratio 0.13; 95% CI 0.05-0.33) and severe exacerbations (0.11; 0.03-0.45). This was not the 
case for eosinophils <0.15x109/L (odds ratio for exacerbations 1.15; 0.51-1.28 and severe 
exacerbations 5.72; 0.97-33.6). There was no consistent interaction between treatment response 
and FeNO or the composite score. 
Conclusions: In patients with mild asthma the effects of as-needed budesonide/formoterol on 
exacerbations are independent of biomarker profile, whereas the benefits of maintenance inhaled 
budesonide are greater in patients with high blood eosinophil counts.  
 
(Funded by AstraZeneca and the Health Research Council of New Zealand; Australian New 










Patients with mild or episodic asthma often struggle to commit to treatment with regular inhaled 
corticosteroids. This is a problem as even minimally symptomatic patients have a risk of 
exacerbations, and the beneficial effect of maintenance inhaled corticosteroid (ICS) therapy on 
exacerbation frequency is substantial1. Identification of a biomarker associated with the risk of 
exacerbations and the likelihood of a response to ICS would be a significant advance. In patients 
with more severe asthma and COPD, sputum and blood eosinophil counts are associated with 
increased risk of exacerbations and identify those most likely to beneficial from ICS2-10. Exhaled 
nitric oxide (FeNO) is also associated with risk of adverse asthma outcomes, and a composite 
score including FeNO and blood eosinophil counts may improve prediction of future risk in severe 
asthma4,5. It is uncertain whether these biomarkers have prognostic value or predict the effect of 
ICS on exacerbations in mild asthma.     
 
The influence of biomarkers on response to treatment was a pre-specified research question in a 
12-month open-label clinical trial of patients with mild asthma, comparing as-needed low-dose 
budesonide-formoterol with as-needed salbutamol and maintenance low-dose budesonide plus as-
needed salbutamol11. We found that there was no significant interaction between baseline blood 
eosinophils, serum periostin, or FeNO and the response to as-needed budesonide/formoterol 
compared to the other treatments for exacerbations, severe exacerbations, or the 5-item Asthma 
Control Questionnaire (ACQ-5)11. In the current study we tested the hypothesis that higher versus 
lower blood eosinophil counts, FeNO, or their combination are associated with greater response to 
either of the budesonide containing treatments versus as-needed salbutamol in the treatment of 
mild asthma.  
  
METHODS  
The study was a 52-week, open-label, parallel-group, randomized controlled trial in 16 clinical trials 
units based in primary and secondary care in New Zealand, the United Kingdom, Italy, and 
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Australia (ACTRN12615000999538)11. All authors had full access to the raw data and no writing 
assistance was provided. Details of the protocol have been published elsewhere.12 
 
Eligible participants were aged 18-75 years and had a self-reported doctor-diagnosis of asthma.  
The main inclusion criteria were use of a short-acting beta-agonist (SABA) as sole asthma therapy 
in the previous 3 months, and requirement for self-reported SABA use of ≥2 occasions in the 
previous 4 weeks, but on average ≤2 occasions per day in the previous 4 weeks. There was no 
minimum requirement for SABA usage for patients with a severe exacerbation in the past 12 
months. Key exclusion criteria were asthma hospitalization in the previous 12 months, and self-
reported smoking history of >20 pack years, and/or onset of respiratory symptoms after the age of 
40 years in current or ex-smokers with ≥10 pack year history. 
 
Randomization and masking 
Randomization was 1:1:1, stratified by country, using a computer-generated sequence with a block 
size of nine.  An electronic clinical record system concealed the participant’s allocation until the 
moment of randomization.  Participants, investigators, and the statistician were not masked to 
group assignment or biomarker results. 
 
Interventions 
After enrolment, participants were randomized to salbutamol pressurized metered dose inhaler (pMDI) 
[Ventolin, GlaxoSmithKline] 100µg, two inhalations as-needed for symptom relief; budesonide [Pulmicort 
Turbuhaler, AstraZeneca] 200µg, one inhalation twice-daily plus salbutamol pMDI [Ventolin] 100µg, two 
inhalations as-needed for symptom relief (maintenance budesonide); or budesonide/formoterol 
[Symbicort Turbuhaler, AstraZeneca] 200/6µg, one inhalation as-needed for symptom relief. Participants 
were provided with asthma action plans with instructions for when to seek medical review for worsening 
asthma, and a log for recording urgent medical visits and systemic corticosteroid use. Electronic inhaler 
monitors (Adherium Ltd, Auckland, New Zealand), which record the date and time of inhaler 





Seven study visits occurred over 52 weeks, at Week 0 (randomization), 6, 12, 22, 32, 42 and 52 
weeks. Spirometry and ACQ-5 were measured at each visit, FeNO at baseline (week 0), week 12 
and week 52 and blood eosinophils at baseline only. Patients were withdrawn due to treatment 
failure if they experienced one severe exacerbation, and/or three exacerbations separated by at 
least seven days, and/or unstable asthma resulting in a change in randomized treatment for >2 
weeks. Patients otherwise remained under their primary care physician for their asthma care 
throughout the period of the trial.  
 
Outcomes  
The primary outcome for this analysis, as for the main study, was the annual rate of asthma 
exacerbations per patient, defined as one or more of the following: worsening asthma resulting in 
an urgent medical care consultation (primary care visit, emergency department (ED) visit or 
hospital admission); a prescription of systemic glucocorticoids for any duration; and/or a high 
beta2-agonist use episode, defined as >16 actuations of albuterol or >8 actuations of 
budesonide/formoterol within 24 hours.  
 
Key secondary outcome variables were the proportion of patients having a severe exacerbation, 
based on ATS/ERS criteria12 of prescription of systemic corticosteroids for at least 3 days because 
of asthma and/or hospitalization or ED visit because of asthma, leading to prescription of systemic 
corticosteroids; ACQ-5 score, the mean of 5 questions about asthma symptoms during the 
previous week, each scored on a 7 point scale between 0 (no impairment) and 6 (maximum 
impairment) with a 0.5 unit change representing the minimal clinically important difference13; and 





The treatment comparisons for this analysis were between as-needed salbutamol and the two 
inhaled corticosteroid-containing groups. The key aims of the analysis were to describe the patient 
characteristics and outcomes, by treatment group, according to baseline biomarker status. 
Biomarker status was defined as low, medium or high using the following criteria, selected on the 
basis of evidence linking them to clinical outcomes and treatment responses in other patient 
populations 2-4,14 : 
 
i) Blood eosinophil levels of <0.15, 0.15-<0.3, and ≥0.3 x 109/L. 
ii) FeNO levels of <20, 20-50, and >50 ppb 
iii) Composite score based on: 1 when FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 when 
FeNO >50 ppb and blood eosinophils ≥0.3 x 109/L, and 2 for any other pattern.  
 
From this study, we have also previously reported the prognostic and predictive value of serum 
periostin15 and a 3-way composite of tertiles of blood eosinophils, FeNO and periostin,11 but 
periostin was not included in the present analysis as work by us and others showed that periostin 
varies substantially between races16 and has disappointing prognostic and predictive 
properties.17,18  
 
Outcomes evaluated were exacerbations (events/patient/year), severe exacerbations (proportion of 
patients with an event); change in ACQ-5, and change in on-treatment FEV1 (L). Changes in the 
last two measures were from baseline to the end of treatment. The primary analysis, for 
exacerbations, was by Poisson regression with an offset for days of observation to estimate rates 
and relative rates of exacerbations, with main effects and interaction terms to account for the 
biomarker status and treatment allocation.  A similar model but using logistic regression was used 
to estimate risks and relative risks of severe exacerbations. Interaction terms tested whether there 
was any evidence of a difference in rates or risks between treatments in relation to eosinophil sub-
group, FeNO sub-group, or composite score. ACQ-5 and FEV1 were analyzed by ANCOVA with 
the baseline measurement as a continuous co-variate and main effects and interaction terms to 
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account for biomarker status and treatment allocation. As this was an exploratory analysis, no 
adjustment was made for multiple comparisons. SAS version 9.4 (SAS Institute Inc., Cary, NC, 
USA) was used for all analyses. 
 
The protocol was approved by all relevant state and national ethics committees. Written informed 
consent was obtained from all patients prior to performance of any study procedures. The trial was 
overseen by an independent data and safety monitoring committee. 
 
RESULTS 
675 participants were randomized between March 2016 and August 2017.  No follow-up data were 
available for 13 participants. No participants were withdrawn by the Sponsor. Participants had mild 
asthma with a mean ACQ-5 score of 1.1; 7.2% reported a severe exacerbation in the previous 12 
months, and 54% reported using SABA on ≤2 occasions/week in the previous 4 weeks. Details of 
the primary study findings have been reported elsewhere.11 
 
Table 1 summarizes the baseline characteristics of participants by eosinophil and FeNO sub-
groups, and by composite score.  Baseline FEV1, ACQ-5 and short acting 2-agonist use were 
similar between biomarker sub-groups but patients with higher blood eosinophil counts, FeNO, and 
composite score were more likely to have been hospitalized with asthma in the past. Patients with 
a FeNO <20 ppb were approximately three times more likely to be current smokers than patients 
with higher FeNO.  
 
As previously reported11, the overall annualised exacerbation rates were 0.4, 0.195 and 0.175 and 
the number of patients experiencing a severe exacerbation were 23, 21, and 9 with as-needed 
salbutamol, maintenance budesonide and as-needed budesonide/formoterol respectively. Eleven 
patients randomised to salbutamol were withdrawn due to treatment failure as indicated by addition 
of ICS or ICS-LABA by the treating physician. In patients randomized to as-needed salbutamol, 
exacerbations and the number of patients having a severe exacerbation increased progressively 
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with increasing blood eosinophil group (Table 2, Figure 1). This trend was significant for severe 
exacerbations (4.5%, 6.5% and 19.5% in low, medium and high sub-groups; p=0.014) and 
remained significant when adjusted for baseline ACQ and FEV1 % predicted (p=0.023); this trend 
was not observed among the other treatment groups (figure 1). 
 
For the comparison of as-needed budesonide/formoterol with as-needed salbutamol, there was no 
significant treatment effect modification in relation to baseline blood eosinophil sub-group, FeNO 
sub-group, and the composite score for either exacerbations or the number of severe 
exacerbations, (table 3, online figure 1). 
 
For the treatment effects of maintenance budesonide compared with as-needed salbutamol, there 
was a significant interaction between blood eosinophil sub-group and the treatment for 
exacerbations (p<0.001) and severe exacerbations (p<0.001; table 3; online figure 1). Maintenance 
budesonide was significantly more effective than as-needed salbutamol in patients in the high 
blood eosinophil sub-group (odds ratio for exacerbations 0.13; 95% CI 0.05, 0.33; and for severe 
exacerbations 0.11; 95% CI 0.03, 0.45). In contrast, in patients in the low eosinophil sub-group, 
maintenance budesonide was no more effective than as-needed salbutamol for exacerbations 
(odds ratio 1.15; 95% CI 0.51, 1.28) and tended to be less effective for severe exacerbation (5.72; 
95% CI 0.97, 33.6).  
 
There was no significant interaction between treatment arms and high versus low baseline FeNO 
(p=0.28) for exacerbation rates, between as-needed budesonide-formoterol and salbutamol 
(p=0.65). However, for severe exacerbations, maintenance budesonide had a greater effect than 
as-needed salbutamol in patients with low compared to high FeNO (p=0.004; table 3; online figure 
1). This difference was unchanged when current smokers (who were over-represented in the low 




There was a greater decrease in ACQ-5 from baseline with maintenance budesonide treatment 
from high to low eosinophil and composite sub-groups, but not for FeNO, or for either biomarker 
with as needed budesonide/formoterol. The mean (95% CI) reduction in ACQ-5 in the high blood 
eosinophil sub-group randomised to maintenance budesonide was 0.5 (0.26, 0.74) compared to 
0.07 (-0.09, 0.33) in patients randomised to as-needed salbutamol (figure 1; table 3). None of the 
treatments was associated with a significant change in on-treatment FEV1 and there were no 





The original open-label randomized controlled trial11 represents the largest study to investigate the 
effect of different inhaled corticosteroid regimes on exacerbations in patients with mild asthma for 
whom there is information on biomarkers of eosinophilic airway inflammation. As such it provides a 
unique opportunity to investigate whether individual biomarkers or their combination are associated 
with the risk of exacerbations in patients treated with as-needed salbutamol, and the treatment 
effects for either regular budesonide plus as-needed salbutamol or as needed 
budesonide/formoterol, each compared with as-needed salbutamol alone. 
 
The most striking finding of our analysis was the relationship between baseline blood eosinophil 
sub-groups and outcomes. Patients in higher baseline blood eosinophil sub-groups were 
approximately three times as likely to have ever had an asthma exacerbation requiring hospital 
admission than those with blood eosinophils <0.15x109/L. In patients randomised to as-needed 
salbutamol alone, exacerbation rates were 60% higher and the proportion of patients having a 
severe exacerbation nearly five times higher if they had baseline blood eosinophils ≥0.3x109/L 
compared to <0.15x109/L. The increased risk of these events was independent of baseline ACQ5 
and FEV1 % predicted indicating that the blood eosinophil count adds prognostic value to a 
traditional assessment based on these measures. This finding is in keeping with consistent 
evidence in more severe asthma2,5 and COPD8 that the blood eosinophil count is an independent 
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prognostic marker of risk for exacerbations. It supports the view that the measurement of blood 
eosinophils is an important component of risk assessment across the spectrum of obstructive lung 
diseases19. 
 
In moderate and severe asthma and in patients with COPD the blood eosinophil count is also a 
predictive biomarker in that it is associated with the treatment response to corticosteroids and 
biologic agents targeting type-2 inflammation2,8,14,20,21. Our findings indicate that this is also the 
case for the response to regular ICS in mild asthma. Compared to as-needed salbutamol alone, 
maintenance budesonide was associated with significantly lower rates of exacerbations and risk of 
severe exacerbations among patients with blood eosinophils ≥0.3x109/L than in those with 
eosinophils <0.15x109/L. There was also an association between the treatment effect on ACQ-5 
and baseline blood eosinophil sub-groups, a finding that has also been reported with ICS treatment 
in patients stratified by sputum eosinophil counts6,7, FeNO22 and composite biomarkers of type-2 
high airway inflammation23.  
 
Unlike maintenance budesonide, the benefits of as-needed budesonide/formoterol compared to as-
needed salbutamol on exacerbations and severe exacerbations were not predicted by the baseline 
blood eosinophil count. A potential explanation is that the formoterol component of as-needed 
budesonide/formoterol prevented the mechanisms that contribute to exacerbations in patients with 
low blood eosinophil counts. Support for this concept is provided by Jayaram et al24, who reported 
that long-acting beta2-agonist treatment prevented exacerbations occurring in patients with asthma 
with low sputum eosinophil counts following targeted corticosteroid treatment. In a crossover 
asthma study, patients with low sputum eosinophil counts responded relatively better to tiotropium 
than ICS compared to patients with a high sputum eosinophil count; but the study periods (12 
weeks) in that study were too short to assess the effect on severe exacerbations.26 Furthermore, in 
patients with COPD and low blood eosinophil counts10,25 there is evidence that long acting 
bronchodilators are more effective than ICS. The alternative possibility that as-needed higher dose 
ICS prevents a temporary increase in eosinophilic airway inflammation occurring at the time of an 
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exacerbations seems less likely because of the complete absence of an effect of maintenance 
budesonide in patients with low baseline blood eosinophil counts. In fact, in this group there was a 
tendency for higher numbers of severe exacerbations so we cannot discount the possibility that 
regular ICS treatment increases the risk of more severe exacerbations occurring in patients with 
low blood eosinophil counts. One potential mechanism of such an effect is promotion of airway 
infection. The increased risk of pneumonia seen with high dose ICS25, evidence of ICS associated 
increase in airway bacteria26, and the delayed recovery and increased risk of treatment failure with 
prednisolone compared to placebo in patients with COPD and low blood eosinophil counts27 all 
support this possibility. Further work incorporating a more complete assessment of airway 
inflammation and infection is needed to fully understand the risks and benefits of maintenance ICS 
in patients with asthma and low blood eosinophil counts.  
 
We found no evidence that FeNO was a prognostic biomarker for exacerbations and, 
counterintuitively, low values were associated with a larger reduction in patients having severe 
exacerbations with maintenance budesonide compared to as needed salbutamol.  In consequence, 
the composite biomarker was less predictive than blood eosinophils alone. This finding is in 
contrast to evidence that FeNO is independently associated with the risk of exacerbation20, the 
short-term response to ICS22 and the efficacy of the biological agent dupilumab in more severe 
asthma5. This difference was not due to the inclusion of more current smokers in the low FeNO 
group because the difference persisted when smokers were excluded from the analyses; allergic 
sensitization, another potentially relevant variable, was not assessed.  Our findings require 
confirmation but one potential explanation is that an additional blood eosinophil dependent, FeNO 
independent, and ICS responsive mechanism is responsible for some severe exacerbations 
particularly in patients with mild asthma treated with salbutamol. 
 
The main limitation of the present study was the open-label design. However, this was important to 
avoid the requirement for double-dummy medication use and thus allow a more real world 
evaluation of as-needed budesonide/formoterol. Nevertheless, we acknowledge that knowledge by 
12 
 
the patient and their clinician of their randomised treatment, and biomarker status might have 
introduced bias. As previously described,11 severe exacerbation results were potentially biased due 
to protocol-driven withdrawal of 11 patients from the salbutamol group (the comparator for the 
present analyses) because their physician initiated maintenance ICS treatment. The overall 
exacerbation rate was lower than anticipated, meaning that our power to identify statistically 
significant difference in exacerbation rates between biomarker categories and treatments is limited. 
Despite this, clear interactions between treatment effects and higher vs lower blood eosinophils 
were seen. For this analysis, we created data categories out of continuous data because these 
categories have existing clinical validity in other contexts,2,3,14,28,29.  However, it might not be valid 
to make the assumption that this would be the case in mild asthma, nor is it necessarily correct to 
assume that there is a linear relationship between highest and lowest categories. It is possible that 
more subtle relationships between biomarkers and outcomes were missed because of our analysis 
plan or because of insufficient power. It is also possible that the identified associations are 
spurious because of type I error inflation although the consistency of the findings for blood 
eosinophils across different outcome measures, the presence of a ‘dose-response’ relationship 
between blood eosinophil category and outcomes and the fact that similar associations have been 
identified by studies in different patient populations2,4,5,8,30 argues against this. Finally, the primary 
outcome of asthma exacerbation rate was based on a composite of worsening asthma resulting in 
urgent medical review, prescription of systemic glucocorticoids, or high beta2-agonist use 
episodes. It is possible that these episodes relate differently to underlying pathophysiological 
mechanisms. It is notable that the clearest signal between the blood eosinophil counts and 
outcomes in patients not treated with ICS was for the prior history ever of exacerbations leading to 
hospitalization and for the proportion of patients having severe exacerbations during the study, 
suggesting that these outcomes are more closely linked to type-2 airway inflammation than the 
composite measure used in the current study.  
  
In conclusion, this clinical trial in adults with mild asthma has shown that the relationship between 
the blood eosinophil count and exacerbations is very different for as-needed salbutamol, as-
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needed budesonide/ formoterol and maintenance budesonide. The benefits of maintenance 
budesonide over as-needed salbutamol increased progressively with increasing blood eosinophil 
category, whereas those of as-needed budesonide/formoterol over as-needed salbutamol for 
preventing exacerbations were independent of baseline biomarkers. FeNO was not consistently 
prognostic or predictive of outcomes and the composite biomarker score added nothing to a blood 
eosinophil based stratification. Our findings do not provide support for the use of regular ICS in 
patients with mild asthma and low eosinophil counts. However, the present findings, together with 
the biomarker analyses already published,11 provide additional support for the generalisability of 
as-needed budesonide-formoterol for reduction of risk of exacerbations and severe exacerbations 
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Figure 1:   
Exacerbations (/patient/year), severe exacerbation (% of patients) and mean (SEM) decrease in 
ACQ by treatment and biomarker category. * Composite score 1 = FeNO <20 ppb and blood 
eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and blood eosinophils ≥0.3 x 109/L, and 2 any other 
pattern. 
 
Online figure 1: 






Table 1: Baseline demographics and characteristics of trial participants by baseline biomarker group 
Values represent mean (SD) unless otherwise stated. FeNO = fraction of exhaled nitric oxide; ppb = parts per billion; BMI=body mass index; 
SABA=short acting beta2-agonist; ACQ-5=Asthma Control Questionnaire 5-item version; eos=eosinophils. * Composite score 1 = FeNO <20 ppb and 




 N (%) 
 Blood eosinophils (x 109/L) FeNO (ppb) Composite score* 
 <0.15 
N=184 
















Female (%) 114 (62) 132 (52) 111 (51) 117 (74) 130 (52) 117 (45) 61 (78) 223 (52) 73 (50) 
Current Smoker 
(%) 
19 (10) 24 (9) 21 (10) 31 (20) 17 (7) 16 (6) 12 (15) 42 (10) 10 (7) 
≥1 exacerbation 
in last year (%) 
16 (9) 14 (5) 18 (8) 9 (6) 23 (9) 17 (7) 6 (8) 30 (7) 12 (8) 
Hospitalisation 
with asthma ever 
(%) 
10 (5.4) 41 (16) 44 (20) 15 (9) 44 (18) 48 (18) 5 (6) 69 (16) 30 (21) 
 Mean (SD) 
Age 36.0 (14.9) 38.1 (14.4) 31.9 (12.3) 36.1 (14.2) 38.0 (14.9) 33.0 (12.9) 36.2 (15.1) 36.7 (14.3) 31.2 (12.1) 
Age at onset of 
asthma 
16.0 (12.9) 15.0 (14.9) 12.3 (11.9) 18.3 (13.9) 14.6 (14.0) 12.0 (12.5) 19.2 (14.1) 14.4 (13.8) 11.7 (11.5) 
BMI 27.3 (7.0) 28.1 (6.5) 26.6 (5.8) 28.7 (7.6) 28.0 (6.5) 26.0 (5.2) 27.7 (7.8) 27.9 (6.5) 25.7 (5.2) 
SABA puffs/week 3.5 (3.3) 3.4 (3.3) 3.6 (3.3) 3.8 (3.7) 3.2 (2.9) 3.6 (3.3) 3.9 (3.5) 3.4 (3.3) 3.6 (3.2) 
ACQ-5 1.01 (0.71) 1.06 (0.69) 1.21 (0.74) 1.22 (0.78) 0.96 (0.67) 1.14 (0.69) 1.12 (0.71) 1.05 (0.71) 1.21 (0.70) 
FEV1 % predicted 92.6 (14.3) 89.2 (13.9) 88.0 (13.0) 92.3 (14.3) 89.1 (13.8) 88.9 (13.4) 95.3 (14.0) 89.5 (13.8) 87.5 (13.0) 
FeNO (ppb) 30.4 (24.8) 45.9 (38.8) 82.9 (50.7) 12.9 (4.0) 33.2 (8.2) 97.7 (42.1) 12.9 (3.9) 42.8 (33.2) 107.3 (42.8) 
Blood eos (x 
109/L) 





Table 2: Exacerbation counts and rates by randomised treatment, and by baseline 
eosinophil, FeNO, and Composite score 
 












(x109/L)     
As-needed salbutamol     
<0.15 49 12 39.53 0.30 (0.17 to 
0.53 
0.15 to <0.3 93 31 76.75 0.40 (0.28 to 
0.57) 




    
<0.15 62 13 44.7 0.29 (0.17 to 
0.50) 
0.15 to <0.3 82 13 68.19 0.19 (0.11 to 
0.33) 




    
<0.15 73 12 65.08 0.18 (0.10 to 
0.32) 
0.15 to <0.3 81 16 69.16 0.23 (0.14 to 
0.38) 
≥0.3 62 8 53.22 0.15 (0.08 to 
0.30) 
FeNO sub-group (ppb)     
As-needed salbutamol     
<20 41 19 31.7 0.60 (0.38 to 
0.94) 
20 to 50 91 29 80.8 0.36 (0.29 to 
0.52) 






    
<20 55 8 44.66 0.18 (0.09 to 
0.36) 
20 to 50 79 12 62.69 0.19 (0.11 to 
0.34) 




    
<20 63 13 53.13 0.24 (0.14 to 
0.42) 
20 to 50 79 14 70.45 0.20 (0.12 to 
0.34) 
>50 78 10 65.98 0.15 ).08 to 
0.28) 
Composite Score*     
As-needed salbutamol     
1 18 5 14.1 0.35 (0.15 to 
0.85) 
2 150 51 126.34 0.40 (0.31 to 
0.53) 




    
1 27 5 20.81 0.24 (0.10 to 
0.58) 
2 140 22 112.9 0.19 (0.13 to 
0.30) 




    
1 33 7 29.1 0.24 (0.11 to 
0.50) 
2 142 21 124.6 0.17 (0.11 to 
0.26) 






* Composite score 1 = FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and 
blood eosinophils ≥0.3 x 109/L, and 2 any other pattern   
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Table 3: Exacerbation and severe exacerbation interaction analysis for treatment effect 
modification for ICS containing treatments compared to as-needed salbutamol. P values on 
the far right refer to the interaction between any treatment effect and the biomarker status. 
P-values of between treatment comparisons were only considered further if this interaction 
was significant. FeNO high = >50 ppb; FeNO low = <20 ppb; blood eosinophil high = ≥0.3 x 
109/L; blood eosinophil low = <0.15 x 109/L; composite score 1 = FeNO <20 ppb and blood 
eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and blood eosinophils ≥0.3 x 109/L, and 2 any 
other pattern 
 










FeNO High 0.53 (0.24 to 1.15) 0.72 (0.35 to 1.50) 0.28 
FeNO Low 0.36 (0.17 to 0.76) 0.19 (0.08 to 0.47)  
P comparison High 
versus Low 
0.51 0.028  
Eosinophil High 0.28 (0.12 to 0.63) 0.13 (0.05 to 0.33) 0.014 
Eosinophil Low 0.63 (0.27 to 1.44) 1.15 (0.51 to 1.28)  
P comparison High 
versus Low 
0.18 <0.001  
Composite score   0.54 
High 0.52 (0.23 to 1.22) 0.24 (0.0.9 to 0.65)  
Low 0.68 (0.22 to 2.14) 0.68 (0.20 to 2.35)  
P comparison High 
versus Low 
0.73 0.20  










FeNO High 0.32 (0.06 to 1.75) 1.93 (0.62 to 5.92) 0.009 
FeNO Low 0.18 (0.04 to 0.84) 0.09 (0.02 to 0.50)  
P comparison High 
versus Low 
0.65 0.004  
Eosinophil High 0.15 (0.03 to 0.79) 0.11 (0.03 to 0.45) 0.009 
Eosinophil Low 1.42 (0.19 to 10.5) 5.72 (0.97 to 33.6)  
P comparison High 
versus Low 
0.10 0.001  
Composite score   0.005 
High 0.15 (0.03 to 0.71) 0.17 (CI 0.05 to 0.65  
Low 0.17 (CI 0.05 to 0.65) 0.31 (0.03 to 3.67)  
P comparison High 
versus Low 




Table 4. Mean (SD) Asthma Control Questionnaire (ACQ) before and after treatment with mean (SD) change by eosinophil count, FeNO and 
composite score. SABA = salbutamol * Composite score 1 = FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and 
blood eosinophils ≥0.3 x 109/L, and 2 any other pattern. 
 
 ACQ baseline ACQ week 52 ACQ change 
Eosinophil sub-group N Mean (SD) N Mean (SD) N Mean (95% CI) 
<0.15       
 As-needed SABA 48 0.99 (0.68) 43 0.76 (0.82) 42 -0.16 (-0.47, 0.15) 
 Budesonide plus as-needed SABA 62 1.04 (0.68) 51 0.80 (0.91) 51 -0.21 (-043, 0.01) 
 As-needed budesonide-formoterol 73 1.01 (0.75) 66 0.74 (0.8) 66 -0.28 (-0.47, -0.09) 
0.15 to <0.3       
 As-needed SABA 93 1.11 (0.76) 80 0.88 (0.78) 80 -0.15 (-0.35, 0.05) 
 Budesonide plus as-needed SABA 82 1.02 (0.66) 71 0.69 (0.65) 71 -0.35 (-0.55, -0.15) 
 As-needed budesonide-formoterol 81 1.03 (0.63) 72 0.66 (0.61) 72 -0.40 (-0.58, -0.22) 
≥0.3       
 As-needed SABA 77 1.10 (0.76) 70 1.03 (1.07) 70 -0.07 (-0.33, 0.19) 
 Budesonide plus as-needed SABA 77 1.23 (0.77) 72 0.77 (0.94) 72 -0.50 (-0.74,-0.26) 
 As-needed budesonide-formoterol 62 1.31 (0.68) 55 0.87 (0.73) 55 -0.43 (-0.66, -0.20) 
 
FeNO sub-group 
<20       
 As-needed SABA 40 1.29 (0.87) 37 1.05 (0.89) 36 -0.12 (-0.48, 0.24) 
 Budesonide plus as-needed SABA 55 1.11 (0.77) 49 0.75 (0.76) 49 -0.37 (-0.65, -0.09) 
 As-needed budesonide-formoterol 63 1.27 (0.73) 57 0.80 (0.87) 57 -0.48 (-0.72, -0.24) 
20 to <50       
 As-needed SABA 91 1.02 (0.68) 80 0.87 (0.83) 80 -0.11 (-0.31, 0.09) 
 Budesonide plus as-needed SABA 79 0.97 (0.70) 63 0.81 (0.96) 63 -0.17 (-0.38, 0.04) 
 As-needed budesonide-formoterol 79 0.89 (0.63) 73 0.65 (0.55) 73 -0.21 (-0.35, -0.07) 
>50       
 As-needed SABA 91 1.05 (0.72) 80 0.88 (0.98) 80 -0.13 (-0.36, 0.10) 
 Budesonide plus as-needed SABA 91 1.19 (0.67) 85 0.68 (0.77) 85 -0.54 (-0.73, -0.35) 






1       
 As-needed SABA 17 1.13 (0.74) 16 0.85 (0.89) 15 -0.11 (-0.66, 0.44) 
 Budesonide plus as-needed SABA 27 0.97 (0.64) 24 0.86 (0.81) 24 -0.07 (-0.37, 0.23) 
 As-needed budesonide-formoterol 33 1.25 (0.75) 31 0.91 (0.98) 31 -0.35 (-0.68, -0.02) 
2       
 As-needed SABA 150 1.04 (0.73) 132 0.88 (0.83) 132 -0.12 (-0.28, 0.03) 
 Budesonide plus as-needed SABA 140 1.08 (0.73) 119 0.76 (0.87) 119 -0.34 (-0.51, -0.17) 
 As-needed budesonide-formoterol 142 1.02 (0.69) 126 0.64 (0.58) 126 -0.38 (-0.51, -0.25) 
3       
 As-needed SABA 51 1.16 (0.76) 45 1.02 (1.13) 45 -0.14 (-0.49, 0.21) 
 Budesonide plus as-needed SABA 54 1.20 (0.68) 51 0.66 (0.78) 51 -0.58 (-0.81, -0.35) 







On line table 1. A. Exacerbation counts and B. Severe exacerbation numbers (%) crude 
rates by FeNO sub-group, smoking status, and randomised treatment.  
 
A. 











As-needed salbutamol only 
FeNO 
Bound 
       
<20 11 22.4 0.49 8 9.3 0.86 0.60 
20-50 25 75.1 0.33 4 5.7 0.70 0.36 
>50 22 70.1 0.31 4 2.1 1.9 0.36 
Maintenance budesonide plus as-needed salbutamol 
 
<20 4 38.8 0.10 4 5.9 0.68 0.18 
20-50 9 57.2 0.16 3 5.5 0.55 0.19 
>50 11 70.7 0.16 1 4.9 0.20 0.16 
As-needed budesonide/formoterol 
 
<20 10 43.7 0.23 3 9.4 0.32 0.24 
20-50 14 69.4 0.20 0 1.0 0 0.20 











 Ever or 
Non-
smoker 
Current Ever or 
Non-
smoker 






      
<20 4/30 (13.3) 3/11 (27.3) 1/46 (2.1) 1/8 (12.5) 2/51 (3.9) 1/12 (8.3) 
20 to 50 2/83 (2.4) 0/8 (0) 8/71 (11.3) 1/8 (12.5) 4/78 (5.1) 0/1 (0) 
>50 12/86 
(14.0) 




On line table 2. Mean (SD) on treatment FEV1 before and after treatment with mean (SD) change by eosinophil count, FeNO and composite 
score. SABA = salbutamol. * Composite score 1 = FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and blood 
eosinophils ≥0.3 x 109/L, and 2 any other pattern. 
 
 FEV1 baseline (L) FEV1 Visit 7 (L) FEV1 visit 7 minus baseline (L) 
Eosinophil sub-group N Mean (SD) N Mean (SD) N Mean (SD) 
<0.15       
 As-needed SABA 49 3.23 (0.73) 42 3.15 (0.62) 42 0.00 (0.25) 
 Budesonide plus as-needed SABA 62 3.24 (0.85) 51 3.18 (0.90) 51 -0.04 (0.27) 
 As-needed budesonide-formoterol 72 3.35 (0.88) 65 3.38 (0.89) 64 0.04 (0.23) 
0.15 to <0.3       
 As-needed SABA 93 3.38 (0.78) 80 3.29 (0.71) 80 -0.04 (0.23) 
 Budesonide plus as-needed SABA 82 3.25 (0.82) 71 3.31 (0.83) 71 0.03 (0.25) 
 As-needed budesonide-formoterol 80 3.17 (0.89) 73 3.13 (0.83) 72 0.00 (0.21) 
≥0.3       
 As-needed SABA 77 3.27 (0.77) 70 3.23 (0.75) 70 0.02 (0.31) 
 Budesonide plus as-needed SABA 77 3.35 (0.93) 72 3.36 (0.93) 72 0.03 (0.24) 
 As-needed budesonide-formoterol 62 3.47 (0.79) 54 3.42 (0.77) 54 0.06 (0.33) 
 
FeNO sub-group 
<20       
 As-needed SABA 41 3.09 (0.65) 37 3.06 (0.59) 37 0.00 (0.15) 
 Budesonide plus as-needed SABA 55 3.05 (0.72) 49 2.99 (0.75) 49 -0.03 (0.27) 
 As-needed budesonide-formoterol 62 3.26 (0.93) 56 3.25 (0.92) 55 0.02 (0.19) 
20 to <50       
 As-needed SABA 91 3.28 (0.70) 79 3.22 (0.71) 79 -0.02 (0.26) 
 Budesonide plus as-needed SABA 79 3.29 (0.88) 63 3.30 (0.90) 63 0.02 (0.24) 
 As-needed budesonide-formoterol 78 3.15 (0.86) 74 3.14 (0.81) 73 0.07 (0.25) 
>50       
 As-needed SABA 91 3.43 (0.84) 80 3.33 (0.75) 80 0.00 (0.3) 
 Budesonide plus as-needed SABA 91 3.47 (0.91) 85 3.51 (0.91) 85 0.04 (0.26) 






1       
 As-needed SABA 17 3.2 (0.77) 16 3.1 (0.63) 16 0.0 (0.19) 
 Budesonide plus as-needed SABA 27 3.1 (0.66) 24 2.92 (0.62) 24 -0.10 (0.24) 
 As-needed budesonide-formoterol 32 3.25 (1.02) 30 3.27 (1.02) 29 0.01 (0.19) 
2       
 As-needed SABA 150 3.34 (0.75) 131 3.26 (0.70) 131 -0.03 (0.24) 
 Budesonide plus as-needed SABA 140 3.28 (0.86) 119 3.31 (0.90) 119 0.02 (0.25) 
 As-needed budesonide-formoterol 141 3.29 (0.86) 127 3.27 (0.82) 126 0.04 (0.25) 
3  
 As-needed SABA 51 3.26 (0.81) 45 3.23 (0.76) 45 0.06 (0.33) 
 Budesonide plus as-needed SABA 54 3.40 (0.95) 51 3.44 (0.93) 51 0.05 (0.25) 
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ABSTRACT   
Background:  Whether blood eosinophil counts and exhaled nitric oxide (FeNO) are associated 
with important outcomes in mild asthma is unclear.  
Methods:  This question was explored in a pre-specified analysis of a 52-week, open-label, 
randomized, parallel-group trial in patients with mild asthma receiving only reliever inhalers, comparing 
salbutamol 200µg as-needed, maintenance budesonide 200µg twice-daily with salbutamol as needed, 
and budesonide/formoterol 200/6µg as-needed. Outcomes were compared between patients with blood 
eosinophils of <0.15, 0.15-<0.3 and ≥0.3x109/L; FeNO  of <20, 20-50 and >50ppb; and a composite 
score based on both.   
Results: The proportion of patients randomised to as-needed salbutamol having a severe 
exacerbation increased progressively with increasing blood eosinophil sub-group (4.1%, 6.5% and 
19.5%; p=0.014).  There were no significant interactions between either biomarker and the effect of 
as-needed budesonide/formoterol compared with as-needed salbutamol for either exacerbations or 
for severe exacerbations. However, there was aere significant interactions between blood 
eosinophil sub-groups and the effect of maintenance budesonide compared with as needed 
salbutamol for exacerbations (p<0.001) (p=0.012p<0.001) and severe exacerbations (p<0.001) 
(p=0.009p=0.001). Maintenance budesonide was more effective than as-needed salbutamol in 
patients with eosinophils ≥0.3x109/L for exacerbations (odds ratio 0.13; 95% CI 0.05-0.33) and 
severe exacerbations (0.11; 0.03-0.45). This was not the case for eosinophils <0.15x109/L (odds 
ratio for exacerbations 1.15; 0.51-1.28 and severe exacerbations 5.72; 0.97-33.6). There was no 
consistent interaction between treatment response and FeNO or the composite score. 
Conclusions: In patients with mild asthma the effects of as-needed budesonide/formoterol on 
exacerbations are independent of biomarker profile, whereas with maintenance inhaled 
budesonide the benefits of maintenance inhaled budesonide are greater in patients with high blood 
eosinophil counts.  
 
(Funded by AstraZeneca and the Health Research Council of New Zealand; Australian New 










Patients with mild or episodic asthma often struggle to commit to treatment with regular inhaled 
corticosteroids. This is a problem as even minimally symptomatic patients have a risk of 
exacerbations, and the beneficial effect of maintenance inhaled corticosteroid (ICS) therapy on 
exacerbation frequency is substantial1. Identification of a biomarker associated with the risk of 
exacerbations and the likelihood of a response to ICS would be a significant advance. In patients 
with more severe asthma and COPD, sputum and blood eosinophil counts are associated with 
increased risk of exacerbations and identify those most likely to a beneficial effect offrom ICS2-10. 
Exhaled nitric oxide (FeNO) is also associated with risk of adverse asthma outcomes, and a 
composite score including FeNO,  and blood eosinophil counts may improve prediction of future 
risk in severe asthma4,5. It is uncertain whether these biomarkers have prognostic value or predict 
the effect of ICS on exacerbations in mild asthma.     
 
In this study we have tested the hypothesis that blood eosinophil counts, FeNO and their 
combination are associated with outcomes in the treatment of mild asthma. The influence of 
biomarkers on response to randomized treatment was a pre-specified research question in a 12-
month open-label clinical trial of patients with mild asthma, comparing as-needed low-dose 
budesonide-formoterol with as-needed salbutamol and maintenance low-dose budesonide plus as-
needed salbutamol11. We have reportefound that there was no significant interaction between 
baseline blood eosinophils, serum periostin, or FeNO and the response to as-needed 
budesonide/formoterol compared to the other treatments for exacerbations, severe exacerbations, 
or the 5-item Asthma Control Questionnaire (ACQ-5)11. In the current study we have tested the 
hypothesis that higher versus lower blood eosinophil counts, FeNO, or their combination are 
associated with greater response to either of the budesonide containing treatments versus as-
needed salbutamol in the treatment of mild asthma.This was a pre-specified research question in 
an open-label clinical trial of patients with mild asthma11. The trial compared the effects of 12 
Comment [B1]: was it serum or plasma?  
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months treatment with as-needed salbutamol, maintenance budesonide, or as-needed 
budesonide/formoterol on exacerbation rates, the number of patients having a severe 
exacerbation, the Asthma Control Questionnaire (ACQ), and on treatment FEV1.  
  
METHODS  
The study was a 52-week, open-label, parallel-group, randomized controlled trial in 16 clinical trials 
units based in primary and secondary care in New Zealand, the United Kingdom, Italy, and 
Australia (ACTRN12615000999538)11. All authors had full access to the raw data and no writing 
assistance was provided. Details of the protocol have been published elsewhere.12 
 
Eligible participants were aged 18-75 years and had a self-reported doctor-diagnosis of asthma.  
The main inclusion criteria were use of a short-acting beta-agonist (SABA) as sole asthma therapy 
in the previous 3 months, and requirement for self-reported SABA use of ≥2 occasions in the 
previous 4 weeks, but on average ≤2 occasions per day in the previous 4 weeks. There was no 
minimum requirement for SABA usage for patients with a severe exacerbation in the past 12 
months. Key exclusion criteria were asthma hospitalization in the previous 12 months, and self-
reported smoking history of >20 pack years, and/or onset of respiratory symptoms after the age of 
40 years in current or ex-smokers with ≥10 pack year history. 
 
Randomization and masking 
Randomization was 1:1:1, stratified by country, using a computer-generated sequence with a block 
size of nine.  An electronic clinical record system concealed the participant’s allocation until the 
moment of randomization.  Participants, investigators, and the statistician were not masked to 
group assignment or biomarker results. 
 
Interventions 
After enrolment, participants were randomized to salbutamol pressurized metered dose inhaler (pMDI) 
[Ventolin, GlaxoSmithKline] 100µg, two inhalations as-needed for symptom relief; budesonide [Pulmicort 
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Turbuhaler, AstraZeneca] 200µg, one inhalation twice-daily plus salbutamol pMDI [Ventolin] 100µg, two 
inhalations as-needed for symptom relief (maintenance budesonide); or budesonide/formoterol 
[Symbicort Turbuhaler, AstraZeneca] 200/6µg, one inhalation as-needed for symptom relief. Participants 
were provided with asthma action plans with instructions for when to seek medical review for worsening 
asthma, and a log for recording urgent medical visits and systemic corticosteroid use. Electronic inhaler 
monitors (Adherium Ltd, Auckland, New Zealand), which record the date and time of inhaler 
actuations, were incorporated in all inhalers dispensed in the study.   
 
Procedures 
Seven study visits occurred over 52 weeks, at Week 0 (randomization), 6, 12, 22, 32, 42 and 52 
weeks. Spirometry and ACQ-5 were measured at each visit, FeNO at baseline (week 0), week 12 
and week 52 and blood eosinophils at baseline only. Patients were withdrawn due to treatment 
failure if they experienced one severe exacerbation, and/or three exacerbations separated by at 
least seven days, and/or unstable asthma resulting in a change in randomized treatment for >2 
weeks. Patients otherwise remained under their primary care physician for their asthma care 
throughout the period of the trial.  
 
Outcomes  
The primary outcome for this analysis, as for the main study, was the annual rate of asthma 
exacerbations per patient, defined as one or more of the following: worsening asthma resulting in 
an urgent medical care consultation (primary care visit, emergency department (ED) visit or 
hospital admission); a prescription of systemic glucocorticoids for any duration; and/or a high 
beta2-agonist use episode, defined as >16 actuations of albuterol or >8 actuations of 
budesonide/formoterol within 24 hours.  
 
Key secondary outcome variables were the proportion of patients having a severe exacerbation, 
based on ATS/ERS criteria12 of prescription of systemic corticosteroids for at least 3 days because 
of asthma and/or hospitalization or ED visit because of asthma, leading to prescription of systemic 
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corticosteroids; ACQ-5 score, the mean of 5 questions about asthma symptoms during the 
previous week, each scored on a 7 point scale between 0 (no impairment) and 6 (maximum 
impairment) with a 0.5 unit change representing the minimal clinically important difference13; and 
on-treatment forced expiratory volume in one second (FEV1). 
 
Statistical Analysis 
The treatment comparisons for this analysis were between as-needed salbutamol and the two 
inhaled corticosteroid-containing groups. The key aims of the analysis were to describe the patient 
characteristics and outcomes, by treatment group, according to baseline biomarker status. 
Biomarker status was defined as low, medium or high using the following criteria, selected on the 
basis of evidence linking them to clinical outcomes and treatment responses in other patient 
populations 2-4,14 : 
 
i) Blood eosinophil levels of <0.15, 0.15-<0.3, and ≥0.3 x 109/L. 
ii) FeNO levels of <20, 20-50, and >50 ppb 
iii) Composite score based on: 1 when FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 when 
FeNO >50 ppb and blood eosinophils ≥0.3 x 109/L, and 2 for any other pattern.  
 
From this study, we have also previously reported the prognostic and predictive value of serum 
periostin15 and a 3-way composite of tertiles of blood eosinophils, FeNO and periostin,11 but 
periostin was not included in the present analysis as work by us and others showed that periostin 
varies substantially between races16 and has disappointing prognostic and predictive 
properties.17,18  
 
Outcomes evaluated were exacerbations (events/patient/year), severe exacerbations (proportion of 
patients with an event); change in ACQ-5, and change in on-treatment FEV1 (L). Changes in the 
last two measures were from baseline to the end of treatment. The primary analysis, for 
exacerbations, was by Poisson regression with an offset for days of observation to estimate rates 
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and relative rates of exacerbations, with main effects and interaction terms to account for the 
biomarker status and treatment allocation.  A similar model but using logistic regression was used 
to estimate risks and relative risks of severe exacerbations. Interaction terms tested whether there 
was any evidence of a difference in rates or risks between treatments in relation to eosinophil sub-
group, FeNO sub-group, or composite score. ACQ-5 and FEV1 were analyzed by ANCOVA with 
the baseline measurement as a continuous co-variate and main effects and interaction terms to 
account for biomarker status and treatment allocation. As this was an exploratory analysis, nNo 
adjustment was made for multiple comparisons. SAS version 9.4 (SAS Institute Inc., Cary, NC, 
USA) was used for all analyses. 
 
The protocol was approved by all relevant state and national ethics committees. Written informed 
consent was obtained from all patients prior to performance of any study procedures. The trial was 
overseen by an independent data and safety monitoring committee. 
 
RESULTS 
675 participants were randomized between March 2016 and August 2017.  No follow-up data were 
available for 13 participants. No participants were withdrawn by the Sponsor. Participants had mild 
asthma with a mean ACQ-5 score of 1.1; 7.2% reported a severe exacerbation in the previous 12 
months, and 54% reported using SABA on ≤2 occasions/week in the previous 4 weeks. Details of 
the primary study findings have been reported elsewhere.11 
 
Table 1 summarizes the baseline characteristics of participants by eosinophil and FeNO sub-
groups, and by composite score.  Baseline FEV1, ACQ-5 and short acting 2-agonist use were 
similar between biomarker sub-groups but patients with higher blood eosinophil counts, FeNO, and 
composite score were more likely to have been hospitalized with asthma in the past. Patients with 
a FeNO <20 ppb were approximately three times more likely to be current smokers than patients 




During the studyAs previously reported11, the overall annualised exacerbation rates were 0.4, 
0.195 and 0.175 and the number of patients experiencing a severe exacerbation were 23, 21, and 
9 with as-needed salbutamol, maintenance budesonide and as-needed budesonide/formoterol 
respectively. Eleven patients randomised to salbutamol were withdrawn due to treatment failure as 
indicated by addition of ICS or ICS-LABA by the treating physician. In patients randomized to as-
needed salbutamol, exacerbations and the number of patients having a severe exacerbation 
increased progressively with increasing blood eosinophil group (Table 2, Figure 1). This trend was 
significant for severe exacerbations (4.5%, 6.5% and 19.5% in low, medium and high sub-groups; 
p=0.014) and; it remained significant when adjusted for baseline ACQ and FEV1 % predicted 
(p=0.023); this trend was not observed for among the other treatment groups (figure 1). 
 
For the comparison of as-needed budesonide/formoterol with as-needed salbutamol, there was no 
significant treatment effect modification in relation to baseline blood eosinophil sub-group, FeNO 
sub-group, and the composite score for either exacerbations or the number of severe 
exacerbations, (table 33, online figure 21). 
 
For the comparison between the treatment effects of maintenance budesonide compared with as-
needed salbutamol, there was a significant interaction between blood eosinophil sub-group and the 
treatment  for exacerbations (p<0.001) and severe exacerbations (p<0.001; table 33; figure 2online 
figure 1). Maintenance budesonide was significantly more effective than as-needed salbutamol in 
patients in the high blood eosinophil sub-group (odds ratio for exacerbations 0.13; 95% CI 0.05, 
0.33; and for severe exacerbations 0.11; 95% CI 0.03, 0.45). In contrast, in patients in the low 
eosinophil sub-group, maintenance budesonide was no more effective than as-needed salbutamol 
for exacerbations (odds ratio 1.15; 95% CI 0.51, 1.28) and tended to be less effective for severe 
exacerbation (5.72; 95% CI 0.97, 33.6).  
 
There was no significant interaction between treatment arms and high versus low baseline FeNO 
(p=0.28) for exacerbation rates, between as-needed budesonide-formoterol and salbutamol 
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(p=0.65). However, for severe exacerbations, maintenance budesonide had a greater effect than 
as-needed salbutamol in patients with low compared to high FeNO (p=0.004; table 33; online 
figure 1). This difference was unchanged when current smokers (who were over-represented in the 
low FeNO sub-group) were excluded (on-line table 11). 
 
There was a greater decrease in ACQ-5 from baseline with maintenance budesonide treatment 
from high to low eosinophil and composite sub-groups, but not for FeNO, or for either biomarker 
with as needed budesonide/formoterol. The mean (95% CI) reduction in ACQ-5 in the high blood 
eosinophil sub-group randomised to maintenance budesonide was 0.5 (0.26, 0.74) compared to 
0.07 (-0.09, 0.33) in patients randomised to as-needed salbutamol (figure 1; table 43). Neither of 
the ICS-containingNone of the treatments was associated with a significant change in on-treatment 
FEV1 and there were no relationships between treatment effect and biomarker sub-groups for this 





The original open-label randomized controlled trial11 represents the largest study to investigate the 
effect of different inhaled corticosteroid regimes on exacerbations in patients with mild asthma for 
whom there is information on biomarkers of eosinophilic airway inflammation. As such it provides a 
unique opportunity to investigate whether individual biomarkers or their combination are associated 
with the risk of exacerbations in patients treated with as-needed salbutamol, and the treatment 
effects for either regular budesonide plus as-needed salbutamol or as needed 
budesonide/formoterol, each compared with as-needed salbutamol alone. 
 
The most striking finding of our analysis was the relationship between baseline blood eosinophil 
sub-groups and outcomes. Patients in higher baseline blood eosinophil sub-groups were 
approximately three times as likely to have ever had an asthma exacerbation requiring hospital 
admission than those with blood eosinophils <0.15x109/L. In patients randomised to as-needed 
10 
 
salbutamol alone, exacerbation rates were 60% higher and the proportion of patients having a 
severe exacerbations nearly five times higher if they had baseline blood eosinophils ≥0.3x109/L 
compared to <0.15x109/L. The increased risk of these events appeared to bewas independent of 
baseline ACQ5 and FEV1 % predicted as these measures did not differ by blood eosinophil 
subgroup suggesindicating that the blood eosinophil count adds prognostic value to a traditional 
assessment based on these measures. This finding is in keeping with consistent evidence in more 
severe asthma2,5 and COPD8 that the blood eosinophil count is an independent prognostic marker 
of risk for exacerbations. It supports the view that the measurement of blood eosinophils is an 
important component of risk assessment across the spectrum of obstructive lung diseases19. 
 
In moderate and severe asthma and in patients with COPD the blood eosinophil count is also a 
predictive biomarker in that it is associated with the treatment response to corticosteroids and 
biologic agents targeting type-2 inflammation2,8,14,20,21. Our findings indicate that this is also the 
case for the response to regular ICS in mild asthma. Compared to as-needed salbutamol alone, 
maintenance budesonide was associated with significantly lower rates of exacerbations and risk of 
severe exacerbations among patients with blood eosinophils ≥0.3x109/L than in those with 
eosinophils <0.15x109/L. There was also an association between the treatment effect on ACQ-5 
and baseline blood eosinophil sub-groups, a finding that has also been reported with ICS treatment 
in patients stratified by sputum eosinophil counts6,7, FeNO22 and composite biomarkers of type-2 
high airway inflammation23.  
 
Unlike maintenance budesonide, the benefits of as-needed budesonide/formoterol compared to as-
needed salbutamol on exacerbations and severe exacerbations were not predicted by the baseline 
blood eosinophil count. A potential explanation is that the formoterol component of as-needed 
budesonide/formoterol prevented the mechanisms that contribute to exacerbations in patients with 
low blood eosinophil counts. Support for this concept is provided by Jayaram et al24, who reported 
that long-acting beta2-agonist treatment prevented exacerbations occurring in patients with asthma 
with low sputum eosinophil counts following targeted corticosteroid treatment. In a crossover 
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asthma study, patients with low sputum eosinophil counts responded relatively better to tiotropium 
than ICS compared to patients with a high sputum eosinophil count; but the study periods (12 
weeks) in this that study were too short to assess the effect on severe exacerbations.26 
Furthermore, in patients with COPD and low blood eosinophil counts10,25 there is evidence that 
long acting bronchodilators are more effective than ICS. The alternative possibility that as-needed 
higher dose ICS prevents a temporary increase in eosinophilic airway inflammation occurring at the 
time of an exacerbations seems less likely because of the complete absence of an effect of 
maintenance budesonide in patients with low baseline blood eosinophil counts. In fact, in this 
group there was a tendency for higher numbers of severe exacerbations so we cannot discount the 
possibility that regular ICS treatment increases the risk of more severe exacerbations occurring in 
patients with low blood eosinophil counts. One potential mechanism of such an effect is promotion 
of airway infection. The increased risk of pneumonia seen with high dose ICS25, evidence of ICS 
associated increase in airway bacteria26, and the delayed recovery and increased risk of treatment 
failure with prednisolone compared to placebo in patients with COPD and low blood eosinophil 
counts27 all support this possibility. Further work incorporating a more complete assessment of 
airway inflammation and infection is needed to fully understand the risks and benefits of 
maintenance ICS in patients with asthma and low blood eosinophil counts.  
 
We found no evidence that FeNO was a prognostic biomarker for exacerbations and, 
counterintuitively, low values were associated with a larger reduction in patients having severe 
exacerbations with maintenance budesonide compared to as needed salbutamol.  In consequence, 
the composite biomarker tended to be was less predictive than blood eosinophils alone. This 
finding is in contrast to evidence that FeNO is independently associated with the risk of 
exacerbation20, the short-term response to ICS22 and the efficacy of the biological agent dupilumab 
in more severe asthma 5. This difference was not due to the inclusion of more current smokers in 
the low FeNO group because the difference persisted when smokers were excluded from the 
analyses; allergic sensitization, ano.ther potentially relevant variable, was not assessed.  It 
doesOur findings require confirmation but one potential explanation s is that an additional blood 
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eosinophil dependent, FeNO independent, and ICS responsive mechanism  is responsible for 
some severe exacerbations particularly in patients with mild asthma treated with salbutamol. 
 
The main limitation of the present study was the open-label design. However, this was important to 
avoid the requirement for double-dummy medication use and thus allow a more real world 
evaluation of as-needed budesonide/formoterol. Nevertheless, we acknowledge that knowledge by 
the patient and their clinician of their randomised treatment, and biomarker status might have 
introduced bias. As previously described,11 severe exacerbation results were likely potentially 
biased due to protocol-driven withdrawal of 11 patients from the salbutamol group (the comparator 
for the present analyses) because their physician initiated maintenance ICS treatment. The overall 
exacerbation rate was lower than anticipated, meaning that our power to identify statistically 
significant difference in exacerbation rates between biomarker categories and treatments is limited. 
Despite this, clear interactions between treatment effects and higher vs lower blood eosinophils 
were seen. For this analysis, wWe created data categories out of continuous data because patient 
and event numbers were were low and these categories have existing clinical validity in different 
other contexts,2,3,14,28,29.  However, it might not be valid to make the assumption that this would be 
the case in mild asthma, nor is it necessarily correct to assume that there is a linear relationship 
between highest and lowest categories. It is possible that more subtle relationships between 
biomarkers and outcomes were missed because of our analysis plan or because of insufficient 
power. In the previous analysis, with eosinophils analysed as a continuous variable,11 there was no 
significant interaction with treatment effect for exacerbations or severe exacerbations as-needed 
budesonide/formoterol compared with either maintenance budesonide or salbutamol. The 
significant result for high versus low eosinophil categories in the present comparison of as-needed 
budesonide/formoterol with salbutamol may be due to a potential threshold effect above the normal 
range of variation. However, iIIt is also possible that the identified associations are spurious 
because of the small numbers of events and type I error inflation although the consistency of the 
findings for blood eosinophils across different outcome measures, the presence of a ‘dose-
response’ relationship between blood eosinophil category and outcomes and the fact that similar 
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associations have been identified by studies in different patient populations2,4,5,8,30 argues against 
this. Finally, the primary outcome of asthma exacerbation rate was based on a composite of 
worsening asthma resulting in urgent medical review, prescription of systemic glucocorticoids, or 
high beta2-agonist use episodes. It is possible that these episodes relate differently to underlying 
pathophysiological mechanisms. It is notable that the clearest signal between the blood eosinophil 
counts and outcomes in patients not treated with ICS was for the prior history ever of 
exacerbations leading to hospitalization and for the proportion of patients having severe 
exacerbations during the study, suggesting that these outcomes are more closely linked to type-2 
airway inflammation than the composite measure used in the current study.  
  
In conclusion, this clinical trial in adults with mild asthma has shown that the relationship between 
the blood eosinophil count and exacerbations is very different for as-needed salbutamol, as-
needed budesonide/ formoterol and maintenance budesonide. The benefits of maintenance 
budesonide over as-needed salbutamol increased progressively with increasing blood eosinophil 
category, whereas those of as-needed budesonide/formoterol over as-needed salbutamol for 
preventing exacerbations were independent of baseline biomarkers. FeNO was not consistently 
prognostic or predictive of outcomes and the composite biomarker score added nothing to a blood 
eosinophil based stratification. Our findings do not provide support for the use of regular ICS in 
patients with mild asthma and low eosinophil counts. However, the present findings, together with 
the biomarker analyses already published,11 provide additional support for the generalisability of 
as-needed budesonide-formoterol for reduction of risk of exacerbations and severe exacerbations 
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Figure 1:   
Exacerbations (/patient/year), severe exacerbation (% of patients) and mean (SEM) decrease in 
ACQ by treatment and biomarker category. * Composite score 1 = FeNO <20 ppb and blood 
eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and blood eosinophils ≥0.3 x 109/L, and 2 any other 
pattern. 
 
Figure Online figure 12: 






Table 1: Baseline demographics and characteristics of trial participants by baseline biomarker group 
Values represent mean (SD) unless otherwise stated. FeNO = fraction of exhaled nitric oxide; ppb = parts per billion; BMI=body mass index; 
SABA=short acting beta2-agonist; ACQ-5=Asthma Control Questionnaire 5-item version; eos=eosinophils. * Composite score 1 = FeNO <20 ppb and 





 N/N1 (%) 
 Blood eosinophils (x 109/L) FeNO (ppb) Composite score* 
 <0.15 
N=184 
















Female (%) 114/180 
(62) 
132 (52) 111 (51) 117 (3274) 130 (3652) 117 (3245) 61 (78) 223 (52) 73 (50) 
Current Smoker 
(%) 
19 (10) 24 (9) 21 (10) 31 (20) 17 (7) 16 (6) 12 (15) 42 (10) 10 (7) 
≥1 exacerbation 
in last year (%) 
16/180 (9) 14 (5) 18 (8) 9 (6) 23 (9) 17 (7) 6 (8) 30 (7) 12 (8) 
Hospitalisation 




41 (16) 44 (20) 15 (9) 44 (18) 48 (18) 5 (6) 69 (16) 30 (21) 
 Mean (SD) 
Age 36.0 (14.9) 38.1 (14.4) 31.9 (12.3) 36.1 (14.2) 38.0 (14.9) 33.0 (12.9) 36.2 (15.1) 36.7 (14.3) 31.2 (12.1) 
Age at onset of 
asthma 
16.0 (12.9) 15.0 (14.9) 12.3 (11.9) 18.3 (13.9) 14.6 (14.0) 12.0 (12.5) 19.2 (14.1) 14.4 (13.8) 11.7 (11.5) 
BMI 27.3 (7.0) 28.1 (6.5) 26.6 (5.8) 28.7 (7.6) 28.0 (6.5) 26.0 (5.2) 27.7 (7.8) 27.9 (6.5) 25.7 (5.2) 
SABA puffs/week 3.5 (3.3) 3.4 (3.3) 3.6 (3.3) 3.8 (3.7) 3.2 (2.9) 3.6 (3.3) 3.9 (3.5) 3.4 (3.3) 3.6 (3.2) 
ACQ-5 1.01 (0.71) 1.06 (0.69) 1.21 (0.74) 1.22 (0.78) 0.96 (0.67) 1.14 (0.69) 1.12 (0.71) 1.05 (0.71) 1.21 (0.70) 
FEV1 % predicted 92.6 (14.3) 89.2 (13.9) 88.0 (13.0) 92.3 (14.3) 89.1 (13.8) 88.9 (13.4) 95.3 (14.0) 89.5 (13.8) 87.5 (13.0) 
FeNO (ppb) 30.4 (24.8) 45.9 (38.8) 82.9 (50.7) 12.9 (4.0) 33.2 (8.2) 97.7 (42.1) 12.9 (3.9) 42.8 (33.2) 107.3 (42.8) 
Blood eos (x 
109/L) 





Table 2: Exacerbation counts and rates by randomised treatment, and by baseline 
eosinophil, FeNO, and Composite score 
 

















(x109/L)      
As-needed salbutamol      
<0.15 49 12 39.53 0.30 (0.17 to 
0.53 
0.30 
0.15 to <0.3 93 31 76.75 0.40 (0.28 to 
0.57) 
0.40 





     
<0.15 62 13 44.7 0.29 (0.17 to 
0.50) 
0.29 
0.15 to <0.3 82 13 68.19 0.19 (0.11 to 
0.33) 
0.19 





     
<0.15 73 12 65.08 0.18 (0.10 to 
0.32) 
0.18 
0.15 to <0.3 81 16 69.16 0.23 (0.14 to 
0.38) 
0.23 
≥0.3 62 8 53.22 0.15 (0.08 to 
0.30) 
0.15 
FeNO sub-group (ppb)      
As-needed salbutamol      
<20 41 19 31.7 0.60 (0.38 to 
0.94) 
0.60 
20 to 50 91 29 80.8 0.36 (0.29 to 
0.52) 
0.36 








     
<20 55 8 44.66 0.18 (0.09 to 
0.36) 
0.18 
20 to 50 79 12 62.69 0.19 (0.11 to 
0.34) 
0.19 





     
<20 63 13 53.13 0.24 (0.14 to 
0.42) 
0.24 
20 to 50 79 14 70.45 0.20 (0.12 to 
0.34) 
0.20 
>50 78 10 65.98 0.15 ).08 to 
0.28) 
0.15 
Composite Score*      
As-needed salbutamol      
1 18 5 14.1 0.35 (0.15 to 
0.85) 
0.35 
2 150 51 126.34 0.40 (0.31 to 
0.53) 
0.40 





     
1 27 5 20.81 0.24 (0.10 to 
0.58) 
0.24 
2 140 22 112.9 0.19 (0.13 to 
0.30) 
0.19 





     
1 33 7 29.1 0.24 (0.11 to 
0.50) 
0.24 
2 142 21 124.6 0.17 (0.11 to 
0.26) 
0.17 







* Composite score 1 = FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and 
blood eosinophils ≥0.3 x 109/L, and 2 any other pattern   
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Table 3Table 3: Exacerbation and severe exacerbation interaction analysis for treatment 
effect modification for ICS containing treatments compared to as-needed salbutamol. P 
values on the far right refer to the interaction between any treatment effect and the 
biomarker status. P-values of between treatment comparisons were only considered further 
if this interaction was significant. FeNO high = >50 ppb; FeNO low = <20 ppb; blood 
eosinophil high = ≥0.3 x 109/L; blood eosinophil low = <0.15 x 109/L; composite score 1 = 
FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and blood eosinophils 
≥0.3 x 109/L, and 2 any other pattern 
 










FeNO High 0.53 (0.24 to 1.15) 0.72 (0.35 to 1.50) 0.28 
FeNO Low 0.36 (0.17 to 0.76) 0.19 (0.08 to 0.47)  
P comparison High 
versus Low 
0.51 0.028  
Eosinophil High 0.28 (0.12 to 0.63) 0.13 (0.05 to 0.33) 0.014 
Eosinophil Low 0.63 (0.27 to 1.44) 1.15 (0.51 to 1.28)  
P comparison High 
versus Low 
0.18 <0.001  
Composite score   0.54 
High 0.52 (0.23 to 1.22) 0.24 (0.0.9 to 0.65)  
Low 0.68 (0.22 to 2.14) 0.68 (0.20 to 2.35)  
P comparison High 
versus Low 
0.73 0.20  










FeNO High 0.32 (0.06 to 1.75) 1.93 (0.62 to 5.92) 0.009 
FeNO Low 0.18 (0.04 to 0.84) 0.09 (0.02 to 0.50)  
P comparison High 
versus Low 
0.65 0.004  
Eosinophil High 0.15 (0.03 to 0.79) 0.11 (0.03 to 0.45) 0.009 
Eosinophil Low 1.42 (0.19 to 10.5) 5.72 (0.97 to 33.6)  
P comparison High 
versus Low 
0.10 0.001  
Composite score   0.005 
High 0.15 (0.03 to 0.71) 0.17 (CI 0.05 to 0.65  
Low 0.17 (CI 0.05 to 0.65) 0.31 (0.03 to 3.67)  
P comparison High 
versus Low 




Table 44. Mean (SD) Asthma Control Questionnaire (ACQ) before and after treatment with mean (SD) change by eosinophil count, FeNO 
and composite score. SABA = salbutamol * Composite score 1 = FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and 
blood eosinophils ≥0.3 x 109/L, and 2 any other pattern. 
 
 ACQ baseline ACQ week 52 ACQ change 
Eosinophil sub-group N Mean (SD) N Mean (SD) N Mean (95% CI) 
<0.15       
 As-needed SABA 48 0.99 (0.68) 43 0.76 (0.82) 42 -0.16 (-0.47, 0.15) 
 Budesonide plus as-needed SABA 62 1.04 (0.68) 51 0.80 (0.91) 51 -0.21 (-043, 0.01) 
 As-needed budesonide-formoterol 73 1.01 (0.75) 66 0.74 (0.8) 66 -0.28 (-0.47, -0.09) 
0.15 to <0.3       
 As-needed SABA 93 1.11 (0.76) 80 0.88 (0.78) 80 -0.15 (-0.35, 0.05) 
 Budesonide plus as-needed SABA 82 1.02 (0.66) 71 0.69 (0.65) 71 -0.35 (-0.55, -0.15) 
 As-needed budesonide-formoterol 81 1.03 (0.63) 72 0.66 (0.61) 72 -0.40 (-0.58, -0.22) 
≥0.3       
 As-needed SABA 77 1.10 (0.76) 70 1.03 (1.07) 70 -0.07 (-0.33, 0.19) 
 Budesonide plus as-needed SABA 77 1.23 (0.77) 72 0.77 (0.94) 72 -0.50 (-0.74,-0.26) 
 As-needed budesonide-formoterol 62 1.31 (0.68) 55 0.87 (0.73) 55 -0.43 (-0.66, -0.20) 
 
FeNO sub-group 
<20       
 As-needed SABA 40 1.29 (0.87) 37 1.05 (0.89) 36 -0.12 (-0.48, 0.24) 
 Budesonide plus as-needed SABA 55 1.11 (0.77) 49 0.75 (0.76) 49 -0.37 (-0.65, -0.09) 
 As-needed budesonide-formoterol 63 1.27 (0.73) 57 0.80 (0.87) 57 -0.48 (-0.72, -0.24) 
20 to <50       
 As-needed SABA 91 1.02 (0.68) 80 0.87 (0.83) 80 -0.11 (-0.31, 0.09) 
 Budesonide plus as-needed SABA 79 0.97 (0.70) 63 0.81 (0.96) 63 -0.17 (-0.38, 0.04) 
 As-needed budesonide-formoterol 79 0.89 (0.63) 73 0.65 (0.55) 73 -0.21 (-0.35, -0.07) 
>50       
 As-needed SABA 91 1.05 (0.72) 80 0.88 (0.98) 80 -0.13 (-0.36, 0.10) 
 Budesonide plus as-needed SABA 91 1.19 (0.67) 85 0.68 (0.77) 85 -0.54 (-0.73, -0.35) 






1       
 As-needed SABA 17 1.13 (0.74) 16 0.85 (0.89) 15 -0.11 (-0.66, 0.44) 
 Budesonide plus as-needed SABA 27 0.97 (0.64) 24 0.86 (0.81) 24 -0.07 (-0.37, 0.23) 
 As-needed budesonide-formoterol 33 1.25 (0.75) 31 0.91 (0.98) 31 -0.35 (-0.68, -0.02) 
2       
 As-needed SABA 150 1.04 (0.73) 132 0.88 (0.83) 132 -0.12 (-0.28, 0.03) 
 Budesonide plus as-needed SABA 140 1.08 (0.73) 119 0.76 (0.87) 119 -0.34 (-0.51, -0.17) 
 As-needed budesonide-formoterol 142 1.02 (0.69) 126 0.64 (0.58) 126 -0.38 (-0.51, -0.25) 
3       
 As-needed SABA 51 1.16 (0.76) 45 1.02 (1.13) 45 -0.14 (-0.49, 0.21) 
 Budesonide plus as-needed SABA 54 1.20 (0.68) 51 0.66 (0.78) 51 -0.58 (-0.81, -0.35) 







On line table 11. A. Exacerbation counts and B. Severe exacerbation numbers (%) crude 
rates by FeNO sub-group, smoking status, and randomised treatment.  
 
A. 











As-needed salbutamol only 
FeNO 
Bound 
       
<20 11 22.4 0.49 8 9.3 0.86 0.60 
20-50 25 75.1 0.33 4 5.7 0.70 0.36 
>50 22 70.1 0.31 4 2.1 1.9 0.36 
Maintenance budesonide plus as-needed salbutamol 
 
<20 4 38.8 0.10 4 5.9 0.68 0.18 
20-50 9 57.2 0.16 3 5.5 0.55 0.19 
>50 11 70.7 0.16 1 4.9 0.20 0.16 
As-needed budesonide/formoterol 
 
<20 10 43.7 0.23 3 9.4 0.32 0.24 
20-50 14 69.4 0.20 0 1.0 0 0.20 











 Ever or 
Non-
smoker 
Current Ever or 
Non-
smoker 






      
<20 4/30 (13.3) 3/11 (27.3) 1/46 (2.1) 1/8 (12.5) 2/51 (3.9) 1/12 (8.3) 
20 to 50 2/83 (2.4) 0/8 (0) 8/71 (11.3) 1/8 (12.5) 4/78 (5.1) 0/1 (0) 
>50 12/86 
(14.0) 




On line table 22. Mean (SD) on treatment FEV1 before and after treatment with mean (SD) change by eosinophil count, FeNO and composite 
score. SABA = salbutamol. * Composite score 1 = FeNO <20 ppb and blood eosinophils <0.15 x 109/L, 3 = FeNO >50 ppb and blood 
eosinophils ≥0.3 x 109/L, and 2 any other pattern. 
 
 FEV1 baseline (L) FEV1 Visit 7 (L) FEV1 visit 7 minus baseline (L) 
Eosinophil sub-group N Mean (SD) N Mean (SD) N Mean (SD) 
<0.15       
 As-needed SABA 49 3.23 (0.73) 42 3.15 (0.62) 42 0.00 (0.25) 
 Budesonide plus as-needed SABA 62 3.24 (0.85) 51 3.18 (0.90) 51 -0.04 (0.27) 
 As-needed budesonide-formoterol 72 3.35 (0.88) 65 3.38 (0.89) 64 0.04 (0.23) 
0.15 to <0.3       
 As-needed SABA 93 3.38 (0.78) 80 3.29 (0.71) 80 -0.04 (0.23) 
 Budesonide plus as-needed SABA 82 3.25 (0.82) 71 3.31 (0.83) 71 0.03 (0.25) 
 As-needed budesonide-formoterol 80 3.17 (0.89) 73 3.13 (0.83) 72 0.00 (0.21) 
≥0.3       
 As-needed SABA 77 3.27 (0.77) 70 3.23 (0.75) 70 0.02 (0.31) 
 Budesonide plus as-needed SABA 77 3.35 (0.93) 72 3.36 (0.93) 72 0.03 (0.24) 
 As-needed budesonide-formoterol 62 3.47 (0.79) 54 3.42 (0.77) 54 0.06 (0.33) 
 
FeNO sub-group 
<20       
 As-needed SABA 41 3.09 (0.65) 37 3.06 (0.59) 37 0.00 (0.15) 
 Budesonide plus as-needed SABA 55 3.05 (0.72) 49 2.99 (0.75) 49 -0.03 (0.27) 
 As-needed budesonide-formoterol 62 3.26 (0.93) 56 3.25 (0.92) 55 0.02 (0.19) 
20 to <50       
 As-needed SABA 91 3.28 (0.70) 79 3.22 (0.71) 79 -0.02 (0.26) 
 Budesonide plus as-needed SABA 79 3.29 (0.88) 63 3.30 (0.90) 63 0.02 (0.24) 
 As-needed budesonide-formoterol 78 3.15 (0.86) 74 3.14 (0.81) 73 0.07 (0.25) 
>50       
 As-needed SABA 91 3.43 (0.84) 80 3.33 (0.75) 80 0.00 (0.3) 
 Budesonide plus as-needed SABA 91 3.47 (0.91) 85 3.51 (0.91) 85 0.04 (0.26) 






1       
 As-needed SABA 17 3.2 (0.77) 16 3.1 (0.63) 16 0.0 (0.19) 
 Budesonide plus as-needed SABA 27 3.1 (0.66) 24 2.92 (0.62) 24 -0.10 (0.24) 
 As-needed budesonide-formoterol 32 3.25 (1.02) 30 3.27 (1.02) 29 0.01 (0.19) 
2       
 As-needed SABA 150 3.34 (0.75) 131 3.26 (0.70) 131 -0.03 (0.24) 
 Budesonide plus as-needed SABA 140 3.28 (0.86) 119 3.31 (0.90) 119 0.02 (0.25) 
 As-needed budesonide-formoterol 141 3.29 (0.86) 127 3.27 (0.82) 126 0.04 (0.25) 
3  
 As-needed SABA 51 3.26 (0.81) 45 3.23 (0.76) 45 0.06 (0.33) 
 Budesonide plus as-needed SABA 54 3.40 (0.95) 51 3.44 (0.93) 51 0.05 (0.25) 
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Many thanks for the positive comments about our manuscript and for arranging the helpful reviews. 
We respond to them as follows: 
Editorial points to be addressed: 
1) In the title please include that this was a pre-specified analysis 
Done 
2) With regard to Reviewer #3 comment 1, p values are not needed for basic characteristics (table 
1) so please do not add.  
Many thanks. We have not done this.  
When you submit the revised paper, please provide one "clean" copy and one copy where your 
changes are tracked. In addition, please provide a separate document listing the comments and 
your replies, point by point. Please also ensure that all elements of the paper and all relevant 
information has been provided. These documents must be supplied as MS Word files. 
Done 
To enable readers to better appreciate research findings and to encourage full and transparent 
reporting of outcomes, The Lancet family journals offer to publish a webaddress in accepted paper 
that links to the study's protocol on the author's institutional website (see Lancet 2009; 373: 992). 
This is particularly encouraged for randomised controlled trials, but is welcome for all types of 
research. 






 I read with interest the article of Pavord et al. that have studied the predictive value of B-Eos and 
FeNO in adults with mild asthma. I think that the studied question is highly relevant and the study 
population is adequate for this topic. However, there are some methodological issues with regard 
to data analysis that I would like the Authors to respond to along with some additional comments 
I have summarized below as major and minor comments. 
Major comments: 
1. I suggest that both FeNO and B-Eos data should have been used continuously for the 
purpose of the present study instead of categories. 
We agree, and in the Introduction have now added that this analysis was done for the comparison of 
as-needed budesonide-formoterol with the other two treatment arms, and no significant modifying 
effect was observed (Beasley et al, NEJM 2019, Figures S12-S17, Tables S56-S58). However, there 
may be a threshold effect above the normal range of variation for blood eosinophils and FeNO, so 
we considered that it was also important to examine associations with categories of high versus low 
*Reply to Reviewers Comments
biomarkers. We were also interested in knowing whether there was any interaction with response to 
maintenance budesonide versus SABA alone. In a separate analysis plan, we therefore pre-specified 
an analysis by categories, choosing those with some pre-existing validity, for the comparison of the 
two ICS-containing arms with SABA alone. We have added a discussion of why the results of these 
analyses may have differed in the discussion (page 12). 
2. I agree that there is no evidence that smoking affects the present results and smoking was 
relatively low prevalent in the studied population. Was any available data on allergic sensitization 
and could that be used to see if IgE sensitization status affects the present results? 
Unfortunately this was not assessed formally so we cannot answer this question. We now discuss 
this limitation (page 11). 
3. The finding that a low FeNO was associated with higher reduction of exacerbations in 
budesonide treated subjects was surprising. I think that the discussion on page 11 around the fact 
that increased B-Eos might represent a steroid sensitive mechanism for exacerbations in mild 
asthma with low FeNO would be strengthened if the Authors would show the data on changes in 
B-Eos over treatment period. 
This is an excellent suggestion but unfortunately we did not measure blood eosinophils after 
randomisation so cannot do this analysis. Previous studies have shown minimal effect of the dose of 
maintenance budesonide on blood eosinophils so it is unlikely that this analysis would be 
informative.  
4. In line with the comment above, it would be interesting to see if there is any information 
regarding change in FeNO over treatment period as well with regard to exacerbation risk. 
We have previously reported the effect of maintenance budesonide and as needed 
budesonide/formoterol on FeNO. There was no significant difference in the median change and both 
differed significantly from the effect of as needed salbutamol  (Beasley et al. NEJM 2019). ICS-
induced change in FeNO is closely correlated with baseline FeNO so it is unlikely that the change in 
FeNO would have better predictive value and the requirement to apply treatment would significant 
limit it as a predictive biomarker in clinical practice. For these reasons this was not part of our 
analysis plan. We are reluctant to do this analysis as it would depart very  significantly from our 
analysis plan.  
5. Even if B-Eos is not related to ACQ or changes in ACQ, it would still be of interest to see a 
subanalysis with regard to ACQ level to understand if the role of biomarkers is affected by baseline 
ACQ. 
We have carried out this analysis and the predictive value of high blood eosinophils on severe 
exacerbations in patients treated with salbutamol alone is independent of baseline ACQ and FEV1. 
This analysis is now presented and discussed on  pages 7 and 9. 
6. The discussion around the role of eosinophils in predicting exacerbations in COPD and effect of 
anti-IL-5 treatment on COPD could be removed or be more nuanced, considering that there is 
evidence also for absence of such correlations (negative studies on B-Eos and exacerbations) and 
the very recent negative study on effect on COPD exacerbations with benralizumab. 
The cited study (Pavord et al. NEJM 2017) showed a relationship between baseline blood eosinophils 
and the response to mepolizumab treatment in patients with COPD so the statement is correct.  
7. The composite score can be removed from the main manuscript as the individual 
biomarkers are behaving differently and just reported in the text that no benefit of combining 
biomarkers was obtained (eventually the results can be part of an online repository). 
This score was an important aspect of our analysis plan and we are reluctant to do this, particularly 
as there is mounting evidence of additive prognostic and predictive value of FeNO and blood 
eosinophils. The negative findings are therefore of significant interest and we feel that readers 
would prefer to see this data in the main paper. 
 
Minor comments 
1. 25 ppb is a more used cut-off than 20 ppb for FeNO. However, I do not think that this 
would change the results so much. 
We agree. The 20 ppb cut point has been suggested by GINA for assessing phenotype in patients 
with severe asthma uncontrolled despite high dose ICS (based on Hanania et al, AJRCCM 2013). This 
cut-off was pre-specified so we prefer to keep the analysis as it is. 
2. I think that it would be of interest to disentangle the different aspects included in the 
exacerbation definition and see if the predictive value of biomarkers differ with regard to chosen 
aspect/outcome.  
We feel we have done this partially by analysing exacerbations and severe exacerbations separately. 
The number of events is too low to sub-divide further. This is already discussed in detail on page 12 
and we don’t think we can say more. 
 
Reviewer #2: Overall comments 
This study aims to evaluate the predictive value of blood eosinophils and exhaled nitric oxide in 
adults with mild asthma. However, I do not think the study was designed properly to achieve the 
study aim. Or the study methods were not described clearly to reflect the design properly. From 
the Table 1, one can see patients with different levels of biomarkers (Blood eosinophils, FeNo) 
were quite different. For example, patients with BE>=0.3 tended to be younger, with lower BMI, 
higher ACQ-5. Composite score 3 were also in a similar situation compared to composite scores of 
1 or 2. However, when comparing the effects of different therapeutic regimes, it was not clear 
whether these baseline difference have been considered or not. Furthermore, within the 52-week 
period, whether any other potential confounding factors were considered? E.g. smoking, alcohol 
drinking, comorbidities.  Without considering aforementioned factors and their potential impact 
on the outcomes, the conclusions cannot be robust & valid.   
We have now carried out an analysis adjusting for baseline ACQ and FEV1 % predicted for patients 
treated with salbutamol alone, and the relationship between blood eosinophils and severe 
exacerbation rate remained significant (see response to reviewer 1’s point 5). Multiple baseline 
characteristics were also investigated in the original study report (Beasley et al, NEJM 2019, Tables 
S56 to S58), and were not found to significantly modify the treatment response. We do not accept 
that there are clinically important differences between groups in most baseline variables. The two 
most obvious differences (smoking rates by baseline FeNO and prior history of severe exacerbation 
by blood eosinophils) are discussed.  
 
Minor comments: 
P6: "No adjustment was made for multiple comparisons." Why not? 
This was an exploratory study and this is now stated in the methods. Please note that we only 
present between treatment group comparisons and p-values when the interaction between 
treatment effect and biomarker category (the main effect) was significant.  
Table 1: what does 114/180 mean (female(%) row first column)? 
This was an error that has been corrected. Data for gender were available for all 184 participants in 
this group.  
Table 2: it would be more informative to provide the confidence intervals for the counts & rates. 
We have added this information. We have already provided confidence intervals for the difference in 
exacerbation rates, which is the analysis of interest.  
Table 3: please state clearly the reference group for each variable.  
This information is now provided in the table legend. 
Table 4: Again, to add confidence intervals will make the table more informative 
Confidence intervals for the mean change in ACQ are provided. 
 
Reviewer #3: General comments: 
This manuscript described a trial in patients with mild asthma who were divided in three 
treatment groups, one group receiving salbutamol as needed, the second group maintenance 
budenoside twice daily plus salbutamol as needed, and the third one budenoside/formoterol as 
needed. It is stated to be the largest such trial so far. Main outcomes were exacerbations and 
severe exacerbations. Results were analyzed and described according to baseline biomarker 
status, blood eosinophils, FENO, or a composite score of the two, with three level subgroups (low, 
medium, high) for each biomarker. The manuscript presents a wealth of numbers. Currently, with 
few p values or significances indicated in the tables and figures, one has to trust that the authors 
have selected the most important obtained differences for their conclusions. It would help the 
reader if statistics were given or indicated in all tables and figures. Among all the data, significant 
results pointed out include that in the salbutamol treatment group severe exacerbations increased 
with the subgroups of increasing blood eosinophil concentration. Maintenance budenoside was 
more effective than as-needed salbutamol only to decrease exacerbations including severe ones in 
the high-eosinophil subgroup. It is concluded that in mild asthma the benefits with maintenance 
budenoside are greater in patients with high eosinophils.  
We have not presented p-values for the baseline demographics, as requested by the editor (see 
above). We have presented a wealth of numbers but our analysis approach was to only  present  P-
values of between treatment comparisons if the interaction analysis for treatment effect 
modification by biomarker status for ICS containing treatments compared to as-needed salbutamol 
was significant. We have made this clear in the analysis section and in the legend to table 3. 
Major comments: 
1) Table 1: Please provide p values or at least indicate what differences may be statistically 
significant differences (p < 0.05) within the biomarker subgroups for each variable, e.g., was there 
a significant difference in hospitalization with asthma ever among the three eosinophil level 
groups? 
Please see the response to the editor’s comment. 
2) Table 2: Please provide p values or indicate significances both within the biomarker 
subgroups as well as for maintenance budenoside or as-needed budenoside/formoterol versus as-
needed salbutamol. 
3) Table 4: Please provide p values or indicate significances for ACQ week 52 versus baseline 
as well as within biomarker subgroups and maintance budenoside or as-needed 
budenoside/formoterol vs as-needed SABA at baseline and week 52. 
4) Figure 1: Please provide p values or indicate signifcances within biomarker subgroups as 
well as for maintenance budenoside or budenoside/formoterol versus salbutamol. 
5) Online table 1: Here too, please provide p values or indicate significances within biomarker 
subgroups as well as for maintenance budenoside or as-needed budenoside/formoterol versus as-
needed salbutamol. 
6) Online table 2: Please provide statistics as for table 4, including for FEV1 at visit 7 versus 
baseline. 
Points 2-6 make the same basic point and we would like to respond to them together. The purpose 
of the analysis was to compare the treatment effects of the ICS containing treatments with the 
effects of as needed salbutamol in different biomarker categories. We have tried to make this 
clearer in the introduction. We do not think it is appropriate to present multiple p-values for within 
group analyses that were not pre-specified or part of our analysis plan. Readers who are interested 
in the within group data can derive it from the tables. 
Minor comments: 
7) Table 1: The percentages under FeNO in the first row (Females) seem incorrect, for 
instance 117/159 cannot be 32%. Please check and correct. 
Many thanks for picking this up. We have corrected these errors. 
8) Figs. 1 and 2, to this reviewer's understanding, show the same data as in some tables (e.g., 
Table 3 and Fig. 2 appear to have or be based on the same data). Following the principle of not 
showing the same data twice or in two ways, please consider moving the relevant tables to the 
online supplement. 
We have moved figure 2 to the online supplement, as suggested. The earlier reviewer has requested 
we keep table 2 and show 95% CI. These are not shown elsewhere so we prefer to keep this table in 
the main paper. 
9) It would be interesting if the authors cared to speculate as to whether one or more of the 
biologics, instead of or in addition to maintenance budenoside, may be beneficial in the high-
eosinophil group in mild asthma (and not only for severe eosinophilic asthma). 
We think this would be highly speculative and well off message for the current paper. It is an 
interesting suggestion though.  
 
Reviewer #4:  
The authors have expanded on a previously published clinical trial to assess the use of blood 
eosinophil levels and/or FeNO in predicting treatment outcomes.  The population is mild asthma 
and three different treatments were assessed over the course of one year.  Treatment groups are 
salbutamol as needed, budesonide (200mcg bid) plus salbutamol as needed and 
budesonide/formoterol (200/6mcg) as needed.  Treatment outcomes were annualized 
exacerbation rate and severe exacerbations previously reported.  Findings are well presented and 
thought provoking. Figure 1 color scheme very clever! 
Many thanks 
 
Some discussion around the potential role of atopic status and/or airway (e.g. sputum) cellular 
phenotyping might help (i.e. atopy likely eosinophilic and therefore ICS responsive whereas 
neutrophilic likely not).  Okay if balanced across groups but potential factor if not. 
We did not assess atopic status and are therefore unable to comment on whether this was a 
confounding factor. We now discuss this limitation on page 11. We agree that a more complete 
assessment of airway inflammation and infection might help us understand the impact of ICS in 
different biomarker groups and we now discuss this (page 11). 
Minor comments: 
Page 2 Abstract - for completeness, suggest including "salbutamol as needed" when describing 
maintenance treatment (as indicated in the methods-interventions section of the manuscript)  
This has been added. 
Page 9 Discussion - I think line 20 needs revision "…consistent evidence in more severe asthma and 
COPD where the blood eosinophil count…" 
This sentence has been revised. 
Page 11 2nd paragraph line 8 - change explanations to explanation  
Done 
Figure 2 Forest plot is not clear/intuitive (perhaps just formatting when printed?) 
We have moved this figure to the online supplement as the data are presented in table 3. We have 
checked it and it is correct. 
 
We found the reviews rigorous, fair and helpful. We all feel that the manuscript has improved 
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